Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: Findings of the phase i part

British Journal of Cancer

Volumn 104, Issue 11, 2011, Pages 1691-1696

  Vermorken, J B ^a   Guigay, J ^b   Mesia, R ^c   Trigo, J M ^d   Keilholz, U ^e   Kerber, A ^f   Bethe, U ^f   Picard, M ^f   Brummendorf, T H ^g,h  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d Department of Oncology   (Spain)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MERCK KGAA   (Germany)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

5 FU; cetuximab; cilengitide; cisplatin; safety; SCCHN

Indexed keywords

CETUXIMAB; CILENGITIDE; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANEMIA; ANGIONEUROTIC EDEMA; ANOREXIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG TOLERANCE; DRY SKIN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOPHOSPHATEMIA; LEUKOCYTE COUNT; LUNG INFECTION; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; NEUTROPHIL COUNT; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; RECURRENT CANCER; SIDE EFFECT; SKIN FISSURE; SQUAMOUS CELL CARCINOMA; STOMATITIS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SQUAMOUS CELL;

EID: 79957671402     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.152     Document Type: Article

References (27)

1. Abdollahi A, Griggs DW, Zieher H, Roth A, Lipson KE, Saffrich R, Grone HJ, Hallahan DE, Reisfeld RA, Debus J, Niethammer AG, Huber PE (2005) Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy. Clin Cancer Res 11: 6270-6279 (Pubitemid 41262958)
2. Bayer (2011) Nexavars (Sorafenib) Summary of Product Characteristics. European Medicines Agency, http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Product-Information/human/000690/WC500 027704.pdf (Accessed 25 March 2011)
3. Beer AJ, Grosu AL, Carlsen J, Kolk A, Sarbia M, Stangier I, Watzlowik P, Wester HJ, Haubner R, Schwaiger M (2007) [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 13: 6610-6616 (Pubitemid 350206795)
4. Bernier J (2009) Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck. Oncol Rev 3: 247-256
5. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL, Kessler H (1999) N-Methylated cyclic RGD peptides as highly active and selective alpha(a)beta(b) integrin antagonists. J Med Chem 42: 3033-3040 (Pubitemid 29384038)
6. Desgrosellier JS, Cheresh DA (2010) Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22
7. Duramed Pharmaceuticals (2011) Zebetas (Bisoprolol Fumarate) Prescribing Information. FDA, http://www.accessdata.fda.gov/drugsatfda- docs/label/2011/ 019982s016lbl.pdf (Accessed 25 March 2011)
8. Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, Van Oosterom AT (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39: 917-926 (Pubitemid 36428623)
9. Fabricius E-M, Wildner G-P, Kruse-Boitschenko U, Hoffmeister B, Goodman SL, Raguse JD (2011) Immunohistochemical analysis of integrins, avb3, avb5 and a5b1, and their ligands, fibrinogen, fibronectin, osteopontin and vitronectin, in frozen sections of human oral head and neck squamous cell carcinomas. Exp Therap Med 2: 9-19
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917
11. Garmy-Susini B, Varner JA (2008) Roles of integrins in tumor angiogenesis and lymphangiogenesis. Lymphat Res Biol 6: 155-163
12. Gibson MK, Li Y, Murphy B, Hussain MH, DeConti RC, Ensley J, Forastiere AA (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23: 3562-3567
13. Gilbert M, Lamborn K, Lassman A, Cloughesy T, Chang S, Lieberman F, Wen P, Potzsch S, Picard M, Prados M, Kuhn J (2007) Tumor tissue delivery of cilengitide after intravenous administration to patients with recurrent glioblastoma (GBM): preliminary data from NABTC protocol 03-02. Neuro Oncol 9: 525. Abstract MA-39
14. Gregoire V, Lefebvre JL, Licitra L, Felip E (2010) Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5): v184-v186
15. 0Bryant CL, Baron A, Gallemann D, Colevas D, Eckhardt SG (2007) Assessment of the biological and pharmacological effects of the alpha n beta3 and alpha n beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors. Ann Oncol 18: 1400-1407 (Pubitemid 47305015)
16. Langer CJ (2008) Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications. Cancer 112: 2635-2645 (Pubitemid 351969206)
17. MacDonald TJ, Stewart CF, Kocak M, Goldman S, Ellenbogen RG, Phillips P, Lafond D, Poussaint TY, Kieran MW, Boyett JM, Kun LE (2008) Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. J Clin Oncol 26: 919-924 (Pubitemid 351398085)
18. Marur S, Forastiere AA (2008) Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 83: 489-501 (Pubitemid 351536473)
19. Merck Serono (2010) Erbituxs (Cetuximab) Summary of Product Characteristics. European Medicines Agency, http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human /000558/WC500029119.pdf (accessed 4 March 2011)
20. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA (2007) Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 25: 1651-1657 (Pubitemid 46797943)
21. National Comprehensive Cancer Network (2010) NCCN Practice Guidelines for Head and Neck Cancers V1 2010. NCCN, http://www.nccn.org/ professionals/ physician-gls/default.asp (Accessed 25 March 2011)
22. Raguse JD, Gath HJ, Bier J, Riess H, Oettle H (2004) Cilengitide (EMD 121974) arrests the growth of a heavily pretreated highly vascularised head and neck tumour. Oral Oncol 40: 228-230 (Pubitemid 38030369)
23. 0Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB (2008) Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610-5617
24. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M (2010a) Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 28: 2712-2718
25. Stupp R, Van den Bent MJ, Erridge SC, Reardon DA, Hong Y, Wheeler H, Hegi ME, Perry JR, Picard M, Weller M (2010b) Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: protocol of a multicenter, randomised, open-label, controlled phase III trial (CENTRIC). J Clin Oncol 28: 15s
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
27. Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359: 1116-1127